Who makes Intra-lymphatic allergenic extract?

Intra-lymphatic allergenic extract is developed by Christopher Thompson, MD.

What development phase is Intra-lymphatic allergenic extract in?

Intra-lymphatic allergenic extract is in Phase 2.

Last reviewed 2026-05-14 · How we verify

Intra-lymphatic allergenic extract

Christopher Thompson, MD · Phase 2 active Biologic

At a glance

Generic name	Intra-lymphatic allergenic extract
Also known as	NDC02686614
Sponsor	Christopher Thompson, MD
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Intra-lymphatic allergenic extract CI brief — competitive landscape report
Intra-lymphatic allergenic extract updates RSS · CI watch RSS
Christopher Thompson, MD portfolio CI